The road to parenthood is not always a bed of roses. It often begins with quiet hope, then the emotional strain grows heavier with every failed attempt. By the time many couples walk into a fertility clinic, they are not just seeking treatment but looking for answers, certainty, and a realistic chance. This is where Preimplantation Genetic Testing, or PGT, comes in as an important part of fertility care. As a modern fertility medicine breakthrough, PGT is a shift from conventional IVF toward a more precise and more informed approach to conception.
IVF has long made it possible to fertilise eggs outside the body and transfer resulting embryos into the uterus. But not every embryo has the same capacity to become a healthy pregnancy. Some embryos may appear perfectly healthy under the microscope yet carry chromosomal abnormalities that prevent implantation or lead to miscarriage.
PGT changes that by allowing fertility specialists to examine embryos created through IVF before they are transferred. By analysing the genetic makeup of those embryos, doctors can identify those that are chromosomally normal or free of certain inherited genetic disorders. The result is better informed embryo selection. This can mean fewer failed transfers, fewer miscarriages and a shorter and less painful fertility journey.
At Nordica, PGT sits within a broader system of advanced reproductive care and is part of a coordinated treatment strategy. Offering PGT requires access to genetic analysis and a strong IVF programme built on disciplined embryology and experienced clinical judgment. One of the most important benefits is improved embryo selection.
Traditionally, embryologists selected embryos largely based on appearance, cell development, and growth pattern. While these indicators are useful, they do not always reveal underlying chromosomal problems. PGT adds another layer of information, telling clinicians not just which embryo looks healthy, but which one is more likely to implant successfully.
Every embryo transfer carries emotional weight. When a transfer fails, it is rarely experienced as just a medical outcome. It feels personal. By helping reduce the transfer of embryos with little realistic chance of success, PGT can reduce the emotional and physical burden that comes with repeated unsuccessful cycles. Its role in reducing miscarriage risk is equally important.
A large proportion of early pregnancy losses are linked to chromosomal abnormalities, and couples often discover this after repeated heartbreak. PGT helps reduce the risk by screening embryos before transfer. While it does not guarantee a successful pregnancy, it improves the odds of transferring an embryo with stronger developmental potential. PGT is especially relevant for specific women of advanced maternal age.
As maternal age increases, the likelihood of chromosomal abnormalities in eggs also rises, so precision matters more. If you are a couple with repeated IVF failures, you stand to benefit. Families with known inherited genetic disorders who want to avoid passing those conditions to their children also stand to benefit. In these situations, PGT becomes more than a technological upgrade. It becomes a clinical strategy rooted in prevention.
Success in fertility treatment is not always visible in the way success is measured in other areas of medicine. It is not always captured in dramatic headlines or neat statistics. Sometimes success is a pregnancy carried to term, or identifying a genetic problem early enough to avoid another failed cycle. Sometimes it is helping a couple understand why previous attempts failed, or it is saving them months or years of emotional exhaustion. That is one of the less obvious but most meaningful contributions of PGT. It provides clarity. And in fertility treatment, clarity is often one of the most valuable things medicines can offer.
The future of PGT in Nigeria appears increasingly significant. Many people still know little about the genetic side of fertility care; IVF itself remains the main concept they understand, but that is changing. Patients are asking more informed questions; they want to know not just whether conception is possible, but how success rates can be improved.
This growing awareness will likely increase demand for more precise fertility treatment. Today, PGT is often discussed mainly in relation to chromosomal screening, but the future may involve broader use for specific inherited disorders. Families with known genetic conditions may increasingly turn to fertility centres not only for conception but for preventive reproductive planning.
Cost, of course, remains a challenge. PGT adds to the financial burden of IVF, even as genetic testing is technically demanding and requires sophisticated laboratory infrastructure. For many Nigerian families, affordability remains a real concern. But the conversation cannot stop at the upfront cost alone.
A more precise embryo transfer can reduce repeated failed cycles, additional medication, extra procedures, and prolonged emotional strain. In many cases, the question is not simply whether PGT costs more; the more relevant question may be whether it helps reduce the total cost of repeated failure. That is where the long-term value begins to make sense.
Lagos is increasingly becoming a destination for fertility care in West Africa, and as Centres like Nordica continue to strengthen advanced reproductive services, Nigeria’s place in regional fertility medicine is also becoming more defined. This means patients may no longer need to look abroad for every advanced reproductive option.
At its heart, the story of PGT at Nordica Lagos is really the story of how fertility medicine is changing. The earlier era of IVF focused mainly on whether fertilisation could happen. The newer era asks a more precise question. For couples facing infertility, that shift can mean fewer failed attempts, fewer losses, and more informed decisions. For Nigeria, it signals something equally important. It shows that fertility medicine is moving beyond access alone and toward precision. That may be where the future truly begins.